Browsing Tag
Terns Pharmaceuticals
5 posts
Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history
Big pharma has $1.3 trillion to deploy and $230 billion in revenue going off-patent by 2030. The 2026 deal map shows where the panic is real.
Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price
Merck cleared a deal hurdle. TERN-701 now has to show whether one CML asset can justify a $6.7bn oncology bet.
Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears
Merck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.
Terns Pharmaceuticals faces market pressure following stock offering announcement
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and…
TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study
TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine…